Since the founding of the company, Roche has been developing innovative solutions for a wide range of chronic and life threatening health conditions that continue to revolutionise healthcare. We continue to be committed to developing medicines and diagnostics that improve people’s lives, delivering rapid, broad and sustainable patient access to our solutions and ultimately transforming healthcare to benefit society and people.
Upcoming Molecules
| Trade (Product) Name |
Generic Name | Indication | Tentative approval | Country of origin |
|---|---|---|---|---|
| Hemlibra | Emicizumab | Routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults and children ≥ 12 y.o with hemophilia A with FVIII inhibitors | May-22 | Japan |
| Rozlytrek | Entrectinib | Treatment of NTRK fusion-positive, locally advanced or metastatic solid tumor adult and pediatric patients Treatment of ROS-1 fusion-positive, locally advanced or metastatic NSCLC |
Jun-22 | USA |
| Gavreto | Pralsetinib | Metastatic RET Fusion-positive NSCLC; RET-Mutant Medullary Thryoid Cancer; RET Fusion-positive Thyroid Cancer; | Jun-22 | USA |
| PHESGO | Pertuzumab / Trastuzumab Fixed Dose Combination | Metastatic Brest Cancer & Early Brest Cancer (neoadjuvant & adjuvant) | Sep-22 | Switzerland |
| Polivy | Polatuzumab vedotin | Combination with rituximab and bendamustine is indicated for the treatment of adult patients with diffuse large B-cell lymphoma who have received at least one prior therapy. | Sep-22 | Switzerland |
| Evrysdi | Risdiplam | Spinal muscular atrophy (SMA) | Sep-22 | Switzerland |
| Enspryng | Satralizumab | Treatment of Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) | Sep-22 | Japan |
| Ronapreve | Casirivimab/imdevimab | Treatment and prevention of SARS-COV-2 infection | Sep-22 | Switzerland |
| Vabysmo | Faricimab | nAMD - neovascular age-related macular degerneration DME - Diabetic macular edema DR - Diaetic rethinopathy (US only) |
Sep-23 | Germany |
| Susvimo | Ranibizumab PDS | neovascular Age related Macular Degenaration (nAMD) | Sep-23 | Germany |
| Ocrevus | Ocrelizumab | Relapsing multiple sclerosis (RMS) & Primary progressive multiple sclerosis (PPMS) | Sep-23 | Germany |
| Mosunetuzumab | 3L relapsed/refractory Follicular Lymphoma | Sep-23 | USA | |
| Glofitamab | 3L+ relapsed/refractory DLBCL | Jun-24 | USA | |
| Tecentriq SC | Atezolizumab | NSCLC + all approved IV indications of Tecentriq IV | Jun-25 | Germany |
| Tiragolumab | Tiragolumab is indicated in combination with atezolizumab, etoposide and carboplatin for the firrst-line treatment of adult patients with extensive stage small cell lung cancer (ES SCLC) | Jun-25 | Switzerland | |
| Giredestrant | 2/3L metastatic Breast Cancer (supported by Ph2 trial) | Jun-25 | Switzerland |